08/20/2015 - 10:20am

The news of the acquisition comes a day after Sprout received FDA approval for its Addyi — dubbed “female Viagra” by many in the lead-up to its approval.

08/20/2015 - 10:05am

Sally Hansen and OPI outperform the Nail Polish CI2 ranking category with generally average performance against key metrics, but with very broad and well-distributed portfolios.

08/20/2015 - 10:05am

Offline Cosmetics market leader Maybelline bats its eyelashes in the mascara category, with a strong search performace across its large product portfolio. 

08/20/2015 - 10:04am

One of the latest innovations from the Korean market has been face-shaped, paper sheet masks that hydrate skin and brighten the complexion. Natural skin and hair care brand Yes To has taken to this innovation and created the Yes To Grapefruit Pore Perfection Paper Mask infused with vitamin C, witch hazel, grapefruit and aloe leaf juice to help reduce hyperpigmentation, correct skin damage and enhance radiance.

08/20/2015 - 10:01am

Tylenol has retaken the OTC pain relief aisle with a vengeance. The brand is close to reclaiming the top spot among internal analgesic tablets behind Aleve and Advil and is growing at a 10% rate on a dollar base of more than $250 million. 

08/20/2015 - 10:01am

The top four best-selling internal analgesic brands — Advil, Aleve, Tylenol and Bayer — generate more than 40% of the overall $3.3 billion in internal analgesic tablet sales, according to IRI figures. But it’s the smaller niche external analgesic brands that are contributing a lot of incremental sales to the pain relief category.

08/20/2015 - 10:01am

Sales of OTC products are ramping up significantly with a $1.5 billion gain over the first six months of 2015. 

08/20/2015 - 9:58am

DSN has partnered with Competitive Promotion Report (CPR) and IRI to create a series of exclusive reports. This article highlights the market performance of major brands in the pain category for both the internal and external analgesic segments.

08/19/2015 - 2:11pm

The company is one of the first to launch a generic version of the discontinued Abilify Oral Solution used to treat depression, bipolar disorder and schizophrenia.